Skip to content

Family-based HIV Prevention for Adolescent Girls

Family-based HIV Prevention for Adolescent Females

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00243126
Enrollment
168
Registered
2005-10-21
Start date
2005-11-30
Completion date
2006-12-31
Last updated
2017-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV prevention, HIV Seronegativity, HIV negative

Brief summary

This is an exploratory/developmental study to support the early phases of development and evaluation of a family-based HIV prevention program for adolescent girls prior to a full-scale trial. Research on the new intervention will include evaluating the feasibility, tolerability, and acceptability of the intervention, and allow us to obtain the preliminary data needed as a pre-requisite to a larger-scale intervention study. Adolescent females and their mother/guardian will be randomized to either: a family-based risk reduction intervention; or a no-treatment control group condition. Participants in both conditions will be assessed at baseline, immediate post-intervention, and at 3- and 6-month follow-ups. A subset of families (12 adolescents and 12 mothers) will participate in a qualitative interview following the 6-month follow-up, in which information will be obtained on participant perception of procedures and intervention content, and whether they have utilized skills taught following the end of the project.

Detailed description

Participants will be involved with the study and follow up for a total of 32 to 36 weeks. 68-84 female adolescents and their mother/guardian (total N = 136-168). African American or mixed race, sexually active female adolescents age 15 to 19 who are at risk for HIV infection and their mother/guardian The adolescent participant and her mother/guardian will be randomized to either a family-based risk reduction intervention or a no-treatment control group condition. Participants in both conditions will be assessed at baseline, immediate post-intervention, and at 3- and 6-month follow-ups. A subset of 24 participants from the intervention condition (12 adolescents and 12 mothers) will participate in a qualitative interview following the 6-month follow-up, in which information will be obtained on participant perception of procedures and intervention content, and whether they have utilized skills taught following the end of the project. Interviewers will collect participant data from the baseline and follow-up behavioral interviews using a Computer Assisted Personal Interviewing (CAPI) method on a portable computer.

Interventions

BEHAVIORALFamily-Based Risk Reduction Intervention

The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
National Institute of Mental Health (NIMH)
CollaboratorNIH
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
15 Years to 19 Years
Healthy volunteers
Yes

Inclusion criteria

* Female * Between the age of 15 years and 0 days and 19 years and 364 days at the time of initial eligibility screening. * Born in the United States * Self identifies as all or part African American. * Sexually active, defined as having had vaginal or anal intercourse * Has engaged in unprotected sex during the past 3 months * Is willing to invite and participate with her mother/guardian in the intervention * Has either a biological mother or a guardian who is willing to participate in the study and meets the eligibility criteria For the purposes of this pilot study, biological mothers are eligible, as are non-biological primary caretakers serving as mother/guardians who have guardianship of the adolescent and with whom the adolescent is living. * Able to understand spoken and written English sufficiently to provide assent/consent and to be interviewed and participate in the study intervention. * Not intending to relocate out of the current geographical area for the duration of study participation. * Provides informed assent or consent Mother or Mother/guardian * Has legal guardianship; and * Currently resides with the adolescent. * Self identifies as all or part African American. * Born in the United States * Able to understand spoken and written English sufficiently to provide consent and to be interviewed and participate in the study intervention. * Not intending to relocate out of the current geographical area for the duration of study participation. * Provides informed consent

Exclusion criteria

* Adolescent is currently pregnant or has carried a pregnancy to term * Adolescent self-reports as HIV positive

Design outcomes

Primary

MeasureTime frameDescription
Test the feasibility of implementing intervention32-26 WeeksThe primary objective of this pilot study is to test the feasibility of implementing a mother-daughter HIV risk reduction intervention for at-risk female adolescents.

Secondary

MeasureTime frameDescription
Conduct a preliminary efficacy test of the intervention32-36 WeeksThe secondary objective of this pilot study is to conduct a preliminary efficacy test of the intervention to determine if trends towards significant effects for reducing unprotected sex and/or reducing substance use are found.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026